幼年特发性关节炎预后相关生物标记物研究进展
Advances in the Study of Prognosis-Related Biomarkers in Juvenile Idiopathic Arthritis
DOI: 10.12677/ACM.2024.142524, PDF,   
作者: 芦家卉, 朱洪涛*：新疆医科大学第一附属医院儿科中心，新疆 乌鲁木齐
关键词: 幼年特发性关节炎；生物标记物；儿童；Juvenile Idiopathic Arthritis； Biomarkers； Children
摘要: 幼年特发性关节炎(JIA)是最常见的儿童慢性风湿性疾病，以慢性关节滑膜炎为主要表现，可伴全身多脏器功能损害，严重威胁患儿的生存质量。相关生物标记物的发现可能有助于早期诊断、评估疾病活动水平、预测临床缓解与复发、预测对药物治疗的反应等，为实现幼年特发性关节炎的合理诊疗提供希望。
Abstract: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in children, with chronic synovitis as the main manifestation, which can be associated with systemic multi-organ functional impairment, seriously threatening the quality of survival of children. The discovery of biomarkers may help in early diagnosis, assessment of disease activity level, prediction of clinical remission and recurrence, and prediction of response to drug therapy, offering hope for rational treatment of juvenile idiopathic arthritis.
文章引用：芦家卉, 朱洪涛. 幼年特发性关节炎预后相关生物标记物研究进展[J]. 临床医学进展, 2024, 14(2): 3758-3763. https://doi.org/10.12677/ACM.2024.142524

参考文献

[1] Prakken, B., Albani, S. and Martini, A. (2011) Juvenile Idiopathic Arthritis. The Lancet, 377, 2138-2149. [Google Scholar] [CrossRef] 
[2] Hinze, C., Gohar, F. and Foell, D. (2015) Management of Juvenile Idiopathic Arthritis: Hitting the Target. Nature Reviews Rheumatology, 11, 290-300. [Google Scholar] [CrossRef] [PubMed]
[3] Ravelli, A., Consolaro, A., Horneff, G., Laxer, R.M., Lovell, D.J., Wulffraat, N.M., Akikusa, J.D., Al-Mayouf, S.M., Antón, J., Avcin, T., et al. (2018) Treating Juvenile Idiopathic Arthri-tis to Target: Recommendations of an International Task Force. Annals of the Rheumatic Diseases, 2018, Article ID: 213030. [Google Scholar] [CrossRef] [PubMed]
[4] Foell, D., Wittkowski, H., Hammerschmidt, I., Wulffraat, N., Schmeling, H., Frosch, M., Horneff, G., Kuis, W., Sorg, C. and Roth, J. (2004) Monitoring Neutrophil Activation in Juvenile Rheumatoid Arthritis by S100A12 Serum Concentrations. Arthritis & Rheumatism, 50, 1286-1295. [Google Scholar] [CrossRef] [PubMed]
[5] Bobek, D., Grčević, D., Kovačić, N., Lukić, I.K. and Jelušić, M. (2014) The Presence of High Mobility Group Box-1 and Soluble Receptor for Advanced Glycation End-Products in Juvenile Idio-pathic Arthritis and Juvenile Systemic Lupus Erythematosus. Pediatric Rheumatology, 12, Article No. 50. [Google Scholar] [CrossRef] [PubMed]
[6] Novick, D., Kim, S., Kaplanski, G. and Dinarello, C.A. (2013) In-terleukin-18, More than a Th1 Cytokine. Seminars in Immunology, 25, 439-448. [Google Scholar] [CrossRef] [PubMed]
[7] Shimizu, M., Nakagishi, Y., Inoue, N., Mizuta, M., Ko, G., Saikawa, Y., Kubota, T., Yamasaki, Y., Takei, S. and Yachie, A. (2015) Interleukin-18 for Predicting the Development of Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis. Clinical Immunology, 160, 277-281. [Google Scholar] [CrossRef] [PubMed]
[8] Schulert, G.S., Yasin, S., Carey, B., Chalk, C., Do, T., Schapiro, A.H., Husami, A., Watts, A., Brunner, H.I., Huggins, J., et al. (2019) Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease: Characterization and Risk Factors. Arthritis & Rheumatology, 71, 1943-1954. [Google Scholar] [CrossRef] [PubMed]
[9] Rood, J.E., Rezk, A., Pogoriler, J., Finn, L.S., Burnham, J.M., Josephson, M.B., Bar-Or, A., Behrens, E.M. and Canna, S.W. (2023) Improvement of Refractory Systemic Juvenile Idiopathic Ar-thritis-Associated Lung Disease with Single-Agent Blockade of IL-1β and IL-18. Journal of Clinical Immunology, 43, 101-108. [Google Scholar] [CrossRef] [PubMed]
[10] Silva, T.A., Garlet, G.P., Lara, V.S., Martins, W., Silva, J.S. and Cunha, F.Q. (2005) Differential Expression of Chemokines and Chemokine Receptors in Inflammatory Periapical Dis-eases. Oral Microbiology and Immunology, 20, 310-316. [Google Scholar] [CrossRef] 
[11] Hasegawa, T., Venkata Suresh, V., Yahata, Y., Nakano, M., Suzuki, S., Suzuki, S., Yamada, S., Kitaura, H., Mizoguchi, I., Noiri, Y., et al. (2021) Inhibition of the CXCL9-CXCR3 Axis Suppresses the Progression of Experimental Apical Periodontitis by Blocking Macrophage Mi-gration and Activation. Scientific Reports, 11, Article No. 2613. [Google Scholar] [CrossRef] [PubMed]
[12] Shimizu, M., Inoue, N., Mizuta, M., Nakagishi, Y. and Yachie, A. (2018) Characteristic Elevation of Soluble TNF Receptor II : I Ratio in Macrophage Activation Syndrome with Sys-temic Juvenile Idiopathic Arthritis. Clinical and Experimental Immunology, 191, 349-355. [Google Scholar] [CrossRef] [PubMed]
[13] Hinze, T., Kessel, C., Hinze, C.H., Seibert, J., Gram, H. and Foell, D. (2021) A Dysregulated Interleukin-18-Interferon- γ-CXCL9 Axis Impacts Treatment Response to Canakinumab in Systemic Ju-venile Idiopathic Arthritis. Rheumatology, 60, 5165-5174. [Google Scholar] [CrossRef] [PubMed]
[14] Wang, S., Song, R., Wang, Z., Jing, Z., Wang, S. and Ma, J. (2018) S100A8/A9 in Inflammation. Frontiers in Immunology, 9, Article No. 1298. [Google Scholar] [CrossRef] [PubMed]
[15] Ahn, J.G. (2020) Role of Biomarkers in Juvenile Idiopathic Arthri-tis. Journal of Rheumatic Diseases, 27, 233-240. [Google Scholar] [CrossRef] 
[16] Frosch, M., Ahlmann, M., Vogl, T., Wittkowski, H., Wulffraat, N., Foell, D. and Roth, J. (2009) The Myeloid-Related Proteins 8 and 14 Complex, a Novel Ligand of Toll-Like Receptor 4, and Interleukin-1β Form a Positive Feedback Mechanism in Systemic-Onset Juvenile Idiopathic Arthritis. Arthritis & Rheumatology, 60, 883-891. [Google Scholar] [CrossRef] [PubMed]
[17] Nirmala, N., Grom, A. and Gram, H. (2014) Biomarkers in Systemic Juve-nile Idiopathic Arthritis: A Comparison with Biomarkers in Cryopyrin-Associated Periodic Syndromes. Current Opinion in Rheumatology, 26, 543-552. [Google Scholar] [CrossRef] 
[18] Miller, Y.I., Choi, S.-H., Wiesner, P., Fang, L., Harkewicz, R., Hartvigsen, K., Boullier, A., Gonen, A., Diehl, C.J., Que, X., et al. (2011) Oxidation-Specific Epitopes Are Dan-ger-Associated Molecular Patterns Recognized by Pattern Recognition Receptors of Innate Immunity. Circulation Re-search, 108, 235-248. [Google Scholar] [CrossRef] 
[19] Ometto, F., Friso, L., Astorri, D., Botsios, C., Raffeiner, B., Punzi, L. and Doria, A. (2017) Calprotectin in Rheumatic Diseases. Experimental Biology and Medicine (Maywood), 242, 859-873. [Google Scholar] [CrossRef] [PubMed]
[20] Romand, X., Bernardy, C., Nguyen, M.V.C., Courtier, A., Trocme, C., Clapasson, M., Paclet, M.-H., Toussaint, B., Gaudin, P. and Baillet, A. (2019) Systemic Cal-protectin and Chronic Inflammatory Rheumatic Diseases. Joint Bone Spine, 86, 691-698. [Google Scholar] [CrossRef] [PubMed]
[21] Altobelli, E., Angeletti, P.M., Petrocelli, R., Lapergola, G., Farello, G., Cannataro, G. and Breda, L. (2021) Serum Calprotectin a Potential Biomarker in Juvenile Idiopathic Arthritis: A Meta-Analysis. Journal of Clinical Medicine, 10, Article No. 4861. [Google Scholar] [CrossRef] [PubMed]
[22] Holzinger, D., Frosch, M., Kastrup, A., Prince, F.H.M., Otten, M.H., Van Suijlekom-Smit, L.W.A., Cate, R., Ten. Hoppenreijs, E.P.A.H., Hansmann, S., Moncrieffe, H., et al. (2012) The Toll-Like Receptor 4 Agonist MRP8/14 Protein Complex Is a Sensitive Indicator for Disease Activity and Predicts Re-lapses in Systemic-Onset Juvenile Idiopathic Arthritis. Annals of the Rheumatic Diseases, 71, 974-980. [Google Scholar] [CrossRef] [PubMed]
[23] Remthangpuii, F., Maheshwari, A., Gulati, S., Sharma, S., Mahto, D. and Chandra, J. (2023) Serum Calprotectin Levels in Different Subtypes of Juvenile Idiopathic Arthritis (JIA) and Its Correlation with Quantitative CRP and JADAS-27. Indian Journal of Pediatrics, 90, 1177-1181. [Google Scholar] [CrossRef] [PubMed]
[24] Gross, C., Belville, C., Lavergne, M., Choltus, H., Jabaudon, M., Blondonnet, R., Constantin, J.-M., Chiambaretta, F., Blanchon, L. and Sapin, V. (2020) Advanced Glycation End Prod-ucts and Receptor (RAGE) Promote Wound Healing of Human Corneal Epithelial Cells. Investigative Ophthalmology & Visual Science, 61, 14. [Google Scholar] [CrossRef] [PubMed]
[25] Yang, H., Wang, H. and Andersson, U. (2020) Targeting Inflammation Driven by HMGB1. Frontiers in Immunology, 11, Article No. 484. [Google Scholar] [CrossRef] [PubMed]
[26] Klune, J.R., Dhupar, R., Cardinal, J., Billiar, T.R. and Tsung, A. (2008) HMGB1: Endogenous Danger Signaling. Molecular Medicine, 14, 476-484. [Google Scholar] [CrossRef] 
[27] Xu, D., Zhang, Y., Zhang, Z.-Y. and Tang, X.-M. (2021) Associa-tion between High Mobility Group Box 1 Protein and Juvenile Idiopathic Arthritis: A Prospective Longitudinal Study. Pediatric Rheumatology, 19, Article No. 112. [Google Scholar] [CrossRef] [PubMed]
[28] Ma, X., Wu, F., Xin, L., Su, G., He, F., Yang, Y., Sun, J. and Liu, Z. (2016) Differential Plasma MicroRNAs Expression in Juvenile Idiopathic Arthritis. Modern Rheumatology, 26, 224-232. [Google Scholar] [CrossRef] [PubMed]

为你推荐